NCI-CTC vs TNS: Which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Commentary

Nature Clinical Practice Neurology

Volumn 4, Issue 2, 2008, Pages 68-69

  Hughes, Richard ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; THALIDOMIDE;

BIOMETRY; CLINICAL ASSESSMENT TOOL; DATA ANALYSIS; DIABETIC NEUROPATHY; DISEASE SEVERITY; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; NATIONAL CANCER INSTITUTE-COMMON TOXICITY CRITERIA; NEUROPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; SHORT SURVEY; SYMPTOMATOLOGY; TOTAL NEUROPATHY SCORE; TOXICITY TESTING; VIBRATION SENSE;

EID: 39049123745     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0740     Document Type: Short Survey

References (3)

1. Merkies IS and Lauria G (2006) 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 16: 149-156
2. Abers J et al. Interventions for preventing neuropathy caused by cisplatin and relaled compounds. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.:
3. Cornblath DR et al. (1999) Total neuropathy score: Validation and reliability study. Neurology 53: 1660-1664